Clinical Trials


A Phase 2b, Randomized, Double Blind, Placebo Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of VX 765 in Subjects With Treatment Resistant Partial Epilepsy With a 24-Week Open-Label Extension

This study is being done to look at the safety, effectiveness and tolerability of VX-765 as an add-on treatment to the existing anti-epileptic medicines in subjects with partial seizures who are resistant to treatment with other anti-epileptic medicines.

Actively recruiting. Contact Tara McTigue RN, CCRC at tmctigue@health.usf.edu.


A Prospective, Multinational, Open-Label, Single-Arm, Explorative Study To Evaluate the Tolerability And Efficacy Of Lacosamide When Added To Levetiracetam With Withdrawal Of The Concomitant Sodium Channel Blocking Antiepileptic Drug In Subjects With Uncontrolled Partial-Onset Seizures Phase 3b

The purpose of this study is to find out if the study drug, lacosamide (LCM) added to Levetiracetam (LEV) is better at controlling seizures and has fewer side effects compared to Levetiracetam with Sodium Channel Blocking AED’s.

Actively recruiting. Contact Tara McTigue RN, CCRC at tmctigue@health.usf.edu.


Open-label study to assess the safety and tolerability of intravenous carbamazepine as short-term replacement of oral carbamazepine in adult patients with epilepsy

This study is being conducted to test the safety and tolerability of an intravenous (IV - directly into a vein) formulation of carbamazepine in subjects with epilepsy. An intravenous formulation of carbamazepine is being tested for use during times when taking medications by mouth is not possible. This study involves staying in the hospital for 7 days.

Actively recruiting. Contact Tara McTigue RN, CCRC at tmctigue@health.usf.edu.